Find and Join

• Let’s talk about that Lilly announcement

  There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats. read more →

• Our response to the op-ed in The Hill

  The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO. read more →

• The shortage ends … then what? (Find out at CCH) 

  We’ve added a new session to the Compounders on Capitol Hill lineup. Don’t miss the discussion of what’s on many a compounder’s (and regulators’ … and reporters’...) mind. read more →

• A new bronze corporate patron

  A big welcome to Ro, APC’s newest tier-level corporate patron! read more →

• Education (and CE) from USP

  For the fourth year in a row, USP will be holding a hybrid live/virtual workshop dedicated to improving the quality of compounding. read more →

• Compounding post-Chevron

  At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.” read more →

• 503B sourcing: our state-by-state analysis

  Do you work for one of APC’s PFMs? If you’re with a Pharmacy/Facility Member, you’ve got access to a new resource. read more →

• What we’ll be talking about at CCH

  When we get together on Capitol Hill to meet with legislators and their staffs, as much as we’d like to talk about a half-dozen issues (easily!), we’re going to be focusing on the three most important.  read more →

More News

Please urge your two US senators to add their names to a letter to FDA led by Senators Tammy Baldwin (WI) and Roger Marshall (KS). It urges the agency to base any action on compounded hormones on legitimate science, and not the faulty recommendations of the 2020 National Academies of Science, Medicine, and Engineering (NASEM) report on compounded hormones—a report that was colored by bias and a remarkable lack of scientific rigor.

We’ve made it easy via our Voter Voice Platform: You can send our pre-written message as is, or you can customize it as you wish. It will take only a couple of minutes. Our platform will even identify your senators for you, based on your state.

The NASEM report ultimately offered six recommendations which, if implemented by FDA would severely restrict—or eliminate entirely—your ability to compound hormones as a therapy for patients suffering hormone imbalance.

While the FDA has taken no action on compounded hormones yet, we must ensure that they don’t do anything that puts patient health at risk or inhibits your ability to treat your patients. We need your voice in this effort.